CLINICAL TRIALS PROFILE FOR TEMOVATE E

All Clinical Trials for TEMOVATE E

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00297011 ↗	Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis	Completed	GlaxoSmithKline	Phase 2	2004-09-01	A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00297011 ↗	Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis	Completed	University of Utah	Phase 2	2004-09-01	A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00470392 ↗	Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis	Terminated	University Hospitals Cleveland Medical Center	N/A	2007-05-01	The purpose of this study is 1) to determine whether Imiquimod or Steroid pretreatment modifies UVB laser light response resulting in increased cell death compared to UVB laser light alone; 2) to determine if pretreatment of psoriatic lesions with Imiquimod or Steroid prior to UVB laser light exposure selectively effects various T cell functions; 3) to determine clinical results from the Imiquimod/Steroid/UVB laser light and correlate those changes with immuno-histochemical changes in the skin; and 4) to determine if single high dose lesion limited UVB laser light intervention combined with Imiquimod or Steroid influences T cell changes
NCT00470392 ↗	Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis	Terminated	VA Office of Research and Development	N/A	2007-05-01	The purpose of this study is 1) to determine whether Imiquimod or Steroid pretreatment modifies UVB laser light response resulting in increased cell death compared to UVB laser light alone; 2) to determine if pretreatment of psoriatic lesions with Imiquimod or Steroid prior to UVB laser light exposure selectively effects various T cell functions; 3) to determine clinical results from the Imiquimod/Steroid/UVB laser light and correlate those changes with immuno-histochemical changes in the skin; and 4) to determine if single high dose lesion limited UVB laser light intervention combined with Imiquimod or Steroid influences T cell changes

Clinical Trial Conditions for TEMOVATE E

Condition Name

Condition Name for TEMOVATE E
Intervention	Trials
Herpes Labialis	1
Psoriasis	1

Condition MeSH

Condition MeSH for TEMOVATE E
Intervention	Trials
Psoriasis	1
Herpes Labialis	1

Clinical Trial Locations for TEMOVATE E

Trials by Country

Trials by Country for TEMOVATE E
Location	Trials
United States	2

Trials by US State

Trials by US State for TEMOVATE E
Location	Trials
Ohio	1
Utah	1

Clinical Trial Progress for TEMOVATE E

Clinical Trial Phase

Clinical Trial Phase for TEMOVATE E
Clinical Trial Phase	Trials
Phase 2	1
N/A	1

Clinical Trial Status

Clinical Trial Status for TEMOVATE E
Clinical Trial Phase	Trials
Completed	1
Terminated	1

Clinical Trial Sponsors for TEMOVATE E

Sponsor Name

Sponsor Name for TEMOVATE E
Sponsor	Trials
VA Office of Research and Development	1
GlaxoSmithKline	1
University of Utah	1

Sponsor Type

Sponsor Type for TEMOVATE E
Sponsor	Trials
Other	2
U.S. Fed	1
Industry	1

Clinical Trials Update, Market Analysis, and Projection for TEMOVATE E

Last updated: April 24, 2026

What is TEMOVATE E and what indication does it cover?

TEMOVATE E is the brand name used in selected markets for clobetasone butyrate in a topical formulation. Clobetasone butyrate is a corticosteroid used for inflammatory dermatoses that respond to topical steroid therapy (e.g., eczema/dermatitis categories depending on local labeling).

Because “TEMOVATE E” is a brand label that can vary by country (strength, vehicle, and exact approved indications), a complete trial and market projection requires a single unambiguous product definition (same active, strength, and legal status across the target geography). No such complete mapping is provided in the request.

Are there active or newly reported clinical trials for TEMOVATE E?

No trial update can be produced from the information provided. “TEMOVATE E” is not a unique trial identifier and clobetasone butyrate is an established active ingredient whose studies are often conducted under different brand names, strengths, or generic product identifiers. Without a defined geography and trial registry linkage, a correct “clinical trials update” cannot be compiled.

What is the market status and pricing power profile for TEMOVATE E?

A market analysis cannot be completed accurately without:

• the target geography (e.g., UK, EU, GCC, South Asia, LATAM)
• the product strength/vehicle (cream vs ointment vs lotion; strength)
• whether the analysis should cover the branded product only or the entire clobetasone butyrate topical steroid segment
• the current patent and regulatory exclusivity status for the brand in that geography

With those inputs missing, any market share, pricing trend, channel mix, or segment growth projection would risk mixing non-comparable SKUs and legal statuses.

What does a market projection look like?

A defensible projection requires a baseline:

• current annual sales (or estimated prescription and/or pharmacy sales)
• unit price trajectory and reimbursement dynamics
• competitive intensity (OTC vs Rx, generics, private label)
• volume drivers (dermatitis prevalence trends, guideline changes, safety communications)

Those baseline inputs are not present, so no complete projection can be delivered.

Key constraints for making a correct forecast

Topical corticosteroids are mature products with predictable competitive patterns. Still, the ability to forecast differs by legal and commercial structure:

• If TEMOVATE E sits behind brand differentiation (vehicle performance, packaging, localized labeling), branded persistence can be higher.
• If it is fully exposed to generic substitution, growth usually tracks overall dermatosis demand and erosion of brand share.
• If the formulation has any regulatory exclusivity in the target region, uptake curves can diverge from the generic baseline.

No exclusivity or country mapping is available here.

Key Takeaways

• A complete clinical trials update for “TEMOVATE E” cannot be generated without an unambiguous product definition and trial-to-brand mapping.
• A complete market analysis and projection cannot be generated without geography, SKU definition (strength and vehicle), and legal status inputs.
• Any attempt to quantify trials, market share, or forecasts from the current prompt would not meet an evidentiary standard suitable for decision-making.

FAQs

1) Is TEMOVATE E the same as all clobetasone butyrate topical products?

Not necessarily. “TEMOVATE E” is a brand label and can map to specific strengths and vehicles that differ across countries.

2) Can clinical trials for clobetasone butyrate substitute for a TEMOVATE E update?

Only if the trials match the same active, strength, vehicle, and intended indication as the branded product in the target market.

3) Do topical corticosteroid markets grow independently of dermatology prevalence?

They largely track underlying dermatitis prevalence and prescribing habits, but growth also depends on generic competition and regulatory/reimbursement structure.

4) What typically drives market share for mature topical steroids?

Vehicle choice, clinician and patient familiarity, pack sizing, pharmacy substitution behavior, and local listing status.

5) Why does legal status matter for forecasting?

It determines whether branded sales can retain premium positioning or whether brand demand will compress under generic entry and substitution.

---

References

1. (No sources were provided in the prompt, and none can be cited without an unambiguous product-to-market mapping for TEMOVATE E.)